August Deals and Funding Rounds Recap
Other articles you may be interested in
SOS1 and SMARCA2 Degraders, RORγ and IRAK4 Inhibitors, and More: January 2024 Compound Collection
The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in January 2024 along with highlights from some of our favorites, including molecules targeting SOS1, NLRP3, SMARCA2, and more.
June 2024 Molecule Roundup
To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.
Patent Highlights: USP19 Inhibitors, KCC2 Potentiators, Nrf2 Inhibitors, Additional Polθ Inhibitors, and More!
Our October patent highlights cover a diverse array of drug discovery IP disclosures. From piperidine-based USP19 inhibitors and small molecule GIPR antagonists for obesity to KCC2 potentiators for epilepsy, the month delivered a number of exciting IP developments. Other notable discoveries include MTA-cooperative PRMT5 inhibitors, direct-acting influenza antivirals against a novel target, Nrf2 activators for heart failure, and a slew of Polθ inhibitors for HR-deficient cancers.
Key Clinical Compound Updates from September 2024
This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.
Patent Highlights: Nurr1 and Nur77 Modulators, STAT3 Inhibitors/Degraders, CDK2 Molecular Glue Degraders, ERAP1 Modulators, and More!
This article highlights key patents published in September 2024, covering a range of therapeutic targets and mechanisms. It includes Nurr1 and Nur77 modulators for oncology applications, STAT3 inhibitors and CRBN-based STAT3 degraders for modulating STAT3 signaling in cancer, and CDK2 molecular glue degraders for estrogen receptor-positive breast cancer resistant to CDK4/CDK6 inhibitors. Additionally, it features ERAP1 modulators for addressing autoimmune diseases, APOL1 inhibitors for APOL1-mediated kidney diseases, and novel NEK7 inhibitors targeting the NLRP3 inflammasome pathway.